. In 11/13 cases only the mutant alleles were expressed suggesting loss or reduced expression of the wild type alleles in these cases. Six of the mutations were also detected in the SCCs from which the lines were derived, strongly suggesting that the mutations occurred, and were selected, in vivo.
In recent years several lines of evidence have characterised p53 as a tumour suppressor gene. There is a frequent loss of heterozygosity at the p53 locus in many types of human tumour which might suggest a reduction to homozygosity of mutated, deleted or rearranged p53 alleles in these cases (Fearon et al., 1987; Yokota et al., 1987; Vogelstein et al., 1988; Baker et al., 1989; Weston et al., 1989) . Furthermore, alterations within the coding sequence of the p53 gene are commonly observed in human cancers , see Hollstein et al., 1991 Caron de Fromentel & Soussi, 1992 for reviews) including squamous cell carcinomas (SCC) of the lung (Chiba et al., 1990 ) oesophagus (Hollstein et al., 1990) anus (Crook et al., 1991b) , larynx (Maestro et al., 1992) , oral cavity (Brachman et al., 1992) and epidermis (Brash et al., 1991 , Pierceall et al., 1991 . Additionally, it is known that many mis-sense p53 mutations induce changes of a probable conformational nature, which increase the half-life of the protein from 20 m (Oren et al., 1981) to several h (Finlay et al., 1988) . As a consequence of this the p53 protein is rendered unusually detectable by conventional Western blotting and immunocytochemical techniques. Significantly, increased p53 protein levels have also been reported in a wide range of human tumours (Cattoretti et al., 1988 , van der Berg et al., 1989 , Bartek et al., 1990a ,b, Iggo et al., 1990 , Rodrigues et al., 1990 including SCC (Field et al., 1991 , Bennett et al., 1991 , Gusterson et al., 1991 Maestro et al., 1992) . The case for p53 as a suppressor gene is further strengthened by the examples of Li-Fraumeni Syndrome (LFS) patients who are predisposed to several cancer types (Li & Fraumeni 1969) and also carry germ-line p53 mutations (Malkin et al., 1990 , Srivastava et al., 1990 , Law et al., 1991 . Some of these LFS patients have also been shown to be heterozygous for the p53 mutation in the somatic tissue but homozygous for the same mutation in the tumour tissue (Malkin et al., 1990 talisation and neoplastic progression (Bischoff et al., , 1991 .
Experimental evidence to support p53 as a tumour suppressor comes from the observation that the wild type p53 gene, but not certain mutants, can exert a reversible (Michalovitz et al., 1990 ) growth suppressive effects. Furthermore, this inhibition of cell proliferation by p53 is specific to transformed cells which harbour an altered p53 gene (Finlay et al., 1989) including those derived from human tumours (Baker et al., 1990 , Mercer et al., 1990 Diller et al., 1990; Casey et al., 1991) . In other instances, the wild type p53 gene can suppress human tumour formation from xenografts (Chen et al., 1990; , Cheng et al., 1992 . It has also been shown that mice which are homozygous for a null p53 mutation are prone to early spontaneous tumour development, indicating that loss of p53 function is enough to contribute to tumour development (Donehower et al., 1992) .
Further support for viewing p53 protein as a tumour suppressor comes from the observations that it is bound (and presumed to be inactivated) by SV40 large T (Lane & Crawford, 1979; Linzer & Levine, 1979) , adenovirus 5 EIB (Sarnow et al., 1982) and human papillomavirus (HPV) E6 proteins (Werness et al., 1990; Crook et al., 1991a) , and may even be inactivated by degradation in the case of HPV16 and HPV18 (Scheffner et al., 1990; Crook et al., 1991a) . The last two viruses are of particular significance to our study since they have been reported to occur in both normal and malignant tissue of the oral cavity (Maitland et al., 1987; 1989 , Yeudall & Campo, 1991 . In addition, transfection of these viruses in vitro into human keratinocytes from both the epidermis (Pirisi et al., 1987; Kaur & McDougall, 1988) and the oral cavity (Park et al., 1991) leads to their immortalisation, and both the E6 and E7 proteins are important for this process (Hawley-Nelson et al., 1989; Munger et al., 1989) . Such immortalised keratinocytes readily progress to malignancy (Hurlin et al., 1991) .
In addition to the evidence supporting a role for p53 as a tumour suppressor gene there is also evidence that some 'gain of function' p53 mutations can give the cells which possess them a growth advantage even in the absence of wild type p53 protein (Wolf et al., 1984; Chen et al., 1990) . Therefore, if the role of p53 mutations in the pathogenesis of SCC is to be understood, the availability of well characterised cell lines carrying p53 alterations would make an important contribution, particularly if the same p53 alterations could be detected in the tumours from which the cell lines were derived (see Sakai & Tsuchida 1992) . In this article we report the frequent detection of p53 mutations and elevated levels of protein in SCC of the epidermis and oral cavity as well as in a series of SCC cell lines which are shown to lack detectable HPV16 and 18 DNA. In six of the cell lines we also show that the p53 mutations present in vitro are also present in vivo.
Materials and methods
Cell culture and SCC cell lines Human epidermal keratinocytes were prepared from infant foreskin samples as described (Parkinson et al., 1986) and grown in Dulbecco's modified Eagle medium (DMEM) containing 20% foetal bovine serum (a selected lot), 0.4 fig ml-I hydrocortisone (Rheinwald & Green, 1975) and 10 ng ml-' cholera toxin (Green, 1978) in the presence of lethally irradiated Swiss 3T3 fibroblasts (Rheinwald & Green, 1975 (Banks et al., 1986) , at 3 tg ml' in CMF-PBS containing 0.1% crystalline bovine serum albumin. The antigens were then visualised by treatment of the specimens with biotinylated second antibody followed by streptavidin as supplied in the Vectastain ABC kit (Vectastain, Peterborough, UK) .
After the final rinse in CMF-PBS pH 7.6 containing 0.15 M NaCI and 0.05% Tween 80 the cells or sections were incubated with 0.6 mg ml' diaminobenzidine (Sigma) and 0.06% hydrogen peroxide (Sigma) in CMF-PBS pH 7.4 for 7-8 min. TBSTM) . Following this the filter was incubated at room temperature with p1801 antibody (1 yg ml-') in TBSTM, rinsed in TBSTM, and incubated with peroxidase-conjugated anti-mouse immunoglobulin (Amersham). After further rinsing the filter was dipped in luminol solution (ECL, Amersham) for one minute and exposed to Kodak X-Omat fast film for 5 min prior to development. Human epidermal keratinocytes and fibroblasts were used as controls for normal p53 levels, JW-2 as a p53 null control and HT29 as a positive control. All films were exposed so that the HT29 positive control produced the same intensity of signal in each blot.
Nucleic acid isolation RNA was extracted from exponentially growing cells using RNAzol B (Cinna/Biotecx), subjected to two ethanol precipitations and stored in aqueous solution at -70°C. Genomic DNA was isolated directly from tumour cryostat sections by lysis of individual sections with 100tlI of lysis buffer containing 10 m Tris-HCI, 10 mM EDTA, 10 mM NaCl, 4% N-lauryl sarcosine and 2.75 mg ml-' proteinase K, followed by overnight digestion at 37°C and EtOH precipitation. The resulting pellet was washed with 80% EtOH, dried, resuspended in 60 tlI TE and stored at 4°C. For PCR amplification this DNA was diluted 1/10 with TE. Genomic DNA was also isolated from cell lines by lysis with 4 M guanidinium thiocyanate followed by differential centrifugation through CsCl solutions, proteinase K digestion, then phenol extracted and EtOH precipitated. This DNA was stored in aqueous solution at 4°C and used to check the mutations found in mRNA in some cases.
Primers
PCR and sequencing primers A, B, D, E and G were those described by Rodrigues et al. (1990) . Downstream PCR primers E and G were 5' biotinylated during synthesis. For PCR amplification and sequencing of DNA the primers described by Brash et al. (1991) were used, the downstream primer of each pair being 5' biotinylated during synthesis (see Figure 6 ).
The full list of primers was, as follows:
The primers for the amplification of HPV-16 and HPV-18 have been described previously (Yeudall & Campo, 1991) and amplify fragments of the E6/E7 (HPV-16) or E6 regions (HPV-18) which are 165 and 99bp respectively.
The HPV16 primers were as follows:
The HPV18 primers were as follows:
The HPRT primers were as follows:
These primers produce a PCR product of 275 bp. SiHa DNA (Single copy HPV-16), W12 (HPV-16) and HeLa (HPV-18) were used as positive controls (see Pater & Pater, 1985) and each PCR reaction was carried out at least five times.
PCR amplification For p53 amplification first strand cDNA was synthesised from 1 fig of total cellular RNA using a Perkin-Elmer Cetus RNA PCR kit, using random hexamers as primers. After the addition of Taq polymerase and 0.15 .LM each PCR primer, amplification proceeded for 35 cycles of 95°C for 1 min and 60°C for 1 min + 2 s extension per cycle. Reaction conditions were as specified by the manufacturer.
Genomic DNA was amplified using a Perkin-Elmer Cetus PCR kit using the following conditions:
Exon 5: Buffer J (Brash et al. 1991) one floor of mouth and one alveolus) and in the three cases where both the primary tumour and the corresponding lymph node metastases from the same patient were available for study the results obtained with the primary and metastatic lesions were the same (see also Figure 1 ). The staining was nuclear in all cases as reported previously (Gusterson et al., 1991; Maestro et al., 1992) . Eighteen SCC cell lines, including eight established from the above tumours (Table II, Figure 2 ), were also studied for the presence of elevated levels of p53 protein. Nine out of eighteen lines showed positive nuclear staining including 2/8 newly established cell lines from the above tumours (Table  III) . In these eight cases there was total agreement between the results obtained with a given cell line and the tumour from which is was derived (Table III) . When protein samples obtained from the cell lines were analysed by Western blotting high steady state levels of p53 protein were observed only in the cell lines that showed a nuclear immunocytochemical staining pattern with p1801 ( Figure 3 , Table III ).
Direct sequencing of the p53 coding region in SCC cell lines and tumours
As there are other possible mechanisms by which p53 protein could be stabilised other than by mutation we isolated mRNAs from several of the positively staining cell lines and subjected them to reverse transcription followed by PCR amplification and direct sequencing. All of these cell lines were found to contain point mutations or in-frame deletions within the coding region of the p53 gene (Table IV) . Figure 4 shows the comparison of a mutant (CGC-*CAC) p53 sequence found at codon 175 (arg-*his) in line SCC-27 (Figure 4(a) as compared to the same region of wild type sequence found in line SCC-4 (Figure 4(b) ). Of the thirteen mutations, eleven were apparently homozygous mutations since there was no evidence of expression of the normal p53 allele and seven of the point mutations have been described previously in other human tumours or cell lines (see Hollstein et al., 1991; Caron de Fromental & Soussi, 1992 for reviews). We have also confirmed the mutation in line SCC-13 previously reported by Brash and co-workers (Brash et al., 1991) .
As with many p53 point mutations four of the seven (including SCC-1 3) resided within the conserved domains of the protein but one other occurred at codon 146 and two others at codon 151 in a region (amino acids 144-166) which has recently been suggested to be a 'hot spot' for tumours of non-small cell tumours of the lung (Mitsudomi et al., 1992) . Even more interestingly, all three of these mutations occurred in cell lines derived from SCCs of the tongue and all occurred at runs of Gs. The G-*A transition at codon 151 (Proline to Histidine) has also been observed previously in an SCC of the epidermis (Brash et al., 1991) .
Five of the mutations were GC to AT transitions including one in line SCC-27 (from a metastatic vulval carcinoma) at a CpG site (Rideout et al., 1990; Jones et al., 1991) . Three mutations were transversions; one GC-*CG (BICR-3), one GC-*TA (BICR-7) and one AT-*CG (SCC-12 Clone B).
The eighth mutation, which occurred in a clone of the line SCC-12 originally derived from the facial epidermis of a kidney transplant patient (SCC-12 clone B; Rheinwald & Beckett, 1981; Parkinson et al., 1983 ) is, to our knowledge, a novel T-*G transversion at the second base of codon 216 which results in the substitution of valine with glycine. Of further interest is the observation that unusually the normal p53 allele was still expressed in SCC-12 Clone B. A nontumorigenic sibling clone from the same tumour SCC-12 Clone F was shown to contain reproducibly less A stop codon also resulted from the frame shift at codon 345 in line BICR22. Expression of a completely normal p53 allele in line BICR-19 was also detected. None of these five lines displayed elevated levels of p53 protein.
Absence of detectable HPV16 and HPV18 DNA in SCC cell lines As it is possible that in the nine SCC lines we have studied where there is no elevation in p53 protein levels, p53 is being aAlso detected in the original tumour sample bData from Jung et al. (1992) .
inactivated by degradation after complexing with an HPV virus such as HPV16 or HPV18 (Werness et al., 1990; Scheffner et al., 1990; Crook et al., 1991a) , we screened our cell lines for the presence of these viruses. All of our cell lines were screened for the presence of HPV16 and 18 DNA by PCR, using DNA from the cell line SiHa as a positive control for a single copy of integrated HPV16 DNA. W12 and HeLa were used as further positive controls for HPV16 and 18 respectively. HPV-compatible, hypoxanthine guanosine phosphoribosyl transferase (HGPRT) primers were used to control for the integrity of each DNA sample and produced a band of approximately 275 bp in all of the SCC samples ( Figure 5 ). Figure 5 also shows that in all of the SCC lines which stained negatively for p53 protein the 165 bp HPV16 and 99 bp HPV18 PCR products were absent. The faint band in the BICR16 track was not reproducible and was in any case too large to be the HPV16 product. This product may be indicative of a low copy number of another closely related HPV type and this is currently being investigated. Other HPV types which have been reported from the oral cavity such as HPV6, HPV-11 (Loning et al., 1985) and HPV-4 (Yeudall & Campo, 1991) are also undetectable in lines SCC-4, SCC-9, SCC-12B, SCC-12F, SCC-13, SCC-15 and SCC-25 (M. Stanley-personal communication; A. Yeudall-personal communication) . These data do not therefore support a role of these viruses in the inactivation of p53 in our series of SCC cell lines. (Figure 1 , see also Purdie et al., 1991) . These results are in keeping with a role for p53 as a regulator of the cell cycle since in both normal and malignant epithelia, proliferation is restricted to the less differentiated cells.
Although in several human tumour systems a good correlation has been noted between the presence of elevated p53 protein levels and the presence of mutations within the coding region of the gene, this had not been investigated for SCC of the epidermis and oral cavity. This is important for the oral cavity in particular where increased p53 protein levels could result from complexing with the HPV E6 protein of HPV types 6 or 11 (Crook et al., 199 la) or be secondary to another oncogenic event. Indeed, helix-loop-helix proteins have been suggested as potential regulators of p53 transcription (Ronen et al., 1991) and one member of this protein family (c-myc) is frequently amplified in SCC of the head and neck (Yokota et al., 1986) . Furthermore, the mdm2 oncogene is known to bind and stabilise the p53 protein in tumours where p53 mutations are absent (Oliner et al., 1992) and elevated p53 levels may also be a consequence of genetic instability (Lu et al., 1992) .
We have so far sequenced the p53 coding region of 14 SCC cell lines including eight of the nine lines which expressed high levels of p53 protein. In all cases where elevated levels of p53 protein were detected, mis-sense mutations, or inframe deletions within the coding region were found, thus agreeing with the assertion that elevated levels of p53 protein are a good indicator of p53 mutation, at least in carcinomas of the head and neck region (see also Maestro et al., 1992) . In the case of the SCC of the upper aerodigestive tract, the mutations we detected were predominantly (4/5) G-*A transitions or G-*T transversions, consistent with the known action of benzo-(a)-pyrene and nitrosamines which are the most abundant classes of carcinogens found in cigarette smoke (IARC 1986 , see also Maestro et al., 1992) . These observations are consistent with cigarette smoking being a major aetiological factor in the generation of these tumours (Stell, 1972) . We also noted that many of the mutations or deletions detected in SCCs of the tongue (3/7) occurred within the region (codons 144-166) which has been reported to be a hot spot for non-small cell lung cancer (Mitsudomi et al., 1992) . Gusterson et al. (1991) also reported that one of two tongue SCC mutations occurred within this region, whereas (Maestro et al., 1992) did not notice any in six of the larynx SCC mutations reported. Although the numbers are small, this might suggest that mutations within the region codons 144-166 are preferentially induced and/or selected at the tongue site, but this clearly needs further investigation. In 7/8 of the cases expression of the normal p53 allele was not detectable, thus indicating that loss of the normal p53 allele or an elimination of its expression had occurred during tumour progression. Normal allele expression was lost even in the case of line SCC-4 which has a proline-*serine amino acid substitution at codon 151 of the p53 gene. This mutation has been reported to drive the wild type protein into the mutant conformation when the two are cotranslated in vitro (Milner & Medcalf, 1991) . If this is the case in intact SCC-4 cells, some wild type p53 activity must remain in the heterozygous state, otherwise it is difficult to explain how the cells which had lost wild-type p53 expression gained a selective advantage in the tumour. In clone SCC-12 clone B however, both the mutated and normal p53 alleles were expressed. Cell line SCC-12 contains populations of tumorigenic (e.g. SCC-12 clone B) and non-tumorigenic (e.g. SCC-12 clone F) keratinocytes the former of which (but not the latter) possess a defect in their ability to respond to terminal differentiation stimuli (Rheinwald & Beckett, 1980; Parkinson et al., 1983) . Interestingly, we have found it difficult to detect the mutant p53 allele in the non-tumorigenic clone F of SCC-12 and this clone also contains far less p53 protein than SCC-12 clone B (Figure 3 compare lane 4 with lane 8) . The heterozygous p53 mutation in line SCC-12 may therefore be an example of a p53 mutation which occurred late in SCC progression and its role in affecting keratinocyte behaviour is currently being explored. The mutation in SCC-12 clone B is to our knowledge novel and is of additional interest since the T-*G transversion in the second base of codon 216 results in the substitution of a glycine for a valine and glycine substitutions have been proposed to introduce folds into amino acid chains thus altering protein conformation (see Gordon et al., 1988) . Several other types of amino acid substitution have previously been noted at codon 216 (Caron de Fromentel & Soussi, 1992) , indicating that this part of the p53 molecule is a relevant site for mutagenesis.
We have also begun to investigate other possible mechanisms of p53 inactivation in our negatively-staining cell lines. Lines BICR-6 and BICR-16 were found to contain stop codon mutations and lines SCC-25, out-of-frame deletions. Line SCC-9 (Table IV) was also recently reported to possess an out of frame deletion (Jung et al., 1992) . Since high levels of proteins were not observed in these lines it seems that these mutant proteins were not stabilised. This would be consistent with the absence of the sequences required for oligomerisation at the carboxy terminus as the epitope for antibody p1801 is close to the amino terminus of the p53 protein (Banks et al., 1986) and should detect the truncated proteins if they were present. The other three negatively staining cell lines are currently being sequenced (see Table  IV ) to determine whether further stop codon mutations are present or whether mis-sense mutations that do not result in elevated levels of p53 protein are present Malkin et al., 1990) . Both of these classes of mutations have already been reported in SCC of the epidermis (Brash et al., 1991; Pierceall et al., 1991) and head and neck (Sakai & Tsuchida, 1992) . Also, mutations in the non-coding region of the gene may effect p53 transcription or translation and we are currently examining this possibility by Northern and Western blotting.
Finally, HPV types 16 and 18 are known to bind and degrade the p53 protein (Werness et al., 1990; Scheffner 1990; Crook et al., 1991a) , so it is possible that any negativelystaining cell lines harbouring these HPV types could have inactivated p53 by this mechanism. This is particularly relevant to oral SCC since HPV16 and 18 are known to occur in the oral cavity (Maitland et al., 1987; 1989; Yeudall & Campo, 1991) and can immortalise oral keratinocytes (Park et al., 1991) . Fifteen of the SCC lines under investigation (including all the negatively-staining ones) were repeatedly screened for HPV-16 and 18 DNA by PCR and were found to be negative. Therefore, p53 has not been inactivated by these HPV types in our cell lines. Our data do not rule out the possibility that there may be other HPV types capable to degrading p53 which are undetectable by the PCR primers we have used, but there is no evidence to support the existence of such viruses at present. It has been suggested that in vitro immortalisation is connected with an important and possibly rate-limiting step in carcinogenesis (Newbold, 1985) , although this has been disputed (Weinberg, 1989; Hunter, 1991) . It is nevertheless interesting that a high frequency of p53 alterations are demonstrable both in vivo (Brash et al., 1991; Pierceall et al., 1991; Field et al., 1991; Gusterson et al., 1991 , Sakai & Tsuchida, 1991 Maestro et al., 1992; Brachman et al., 1992 , this study) and in vitro (Gusterson et al., 1991; Sakai & Tsuchida, 1991, this study) in a cell type which frequently displays the property of in vitro immortalisation (Easty et al., 1981; Rheinwald & Beckett, 1981) . It is also noteworthy that fibroblasts derived from individuals with the Li-Fraumeni syndrome carrying germ-line p53 mutations are prone to spontaneous in vitro immortalisation and when mouse (Harvey & Levine, 1991) or chicken (Ulrich et al., 1992) cells spontaneously immortalise in vitro p53 alterations are usually seen.
The current series of human SCC cell lines offer an opportunity to investigate the role of p53 in the pathogenesis of human SCC including its possible role in cellular immortalisation.
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